Opening book details…
Can I read Risk of Infection Associated with Targeted Therapies for Solid Organ and Hematological Malignancies on EtoBox?
Risk of Infection Associated with Targeted Therapies for Solid Organ and Hematological Malignancies by Isabel Ruiz-Camps; Juan Aguilar-Company is a Medicine article available to read on EtoBox.
What is Risk of Infection Associated with Targeted Therapies for Solid Organ and Hematological Malignancies about?
Higher risks of infection are associated with some targeted drugs used to treat solid organ and hematological malignancies, and an individual patient’s risk of infection is strongly influenced by underlying diseases and concomitant or prior treatments. This review focuses on risk levels and specific suggestions for management, analyzing groups of agents associated with a significant effect on the risk of infection. Due to limited clinical experience and ongoing advances in these therapies, recommendations may be revised in the near future. Bruton tyrosine kinase (BTK) inhibitors are associated with a higher rate of infections, including invasive fungal infection, especially in the first months of treatment and in patients with advanced, pretreated disease. Phosphatidylinositol 3-kinase (PI3K) inhibitors are associated with an increased risk of __Pneumocystis__ pneumonia and cytomegalovirus (CMV) reactivation. Venetoclax is associated with cytopenias, respiratory infections, and fever and neutropenia. Janus kinase (JAK) inhibitors may predispose patients to opportunistic and fungal infections; need for prophylaxis should be assessed on an individual basis. Mammalian target of rapamy
Who reads Risk of Infection Associated with Targeted Therapies for Solid Organ and Hematological Malignancies?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Isabel Ruiz-Camps; Juan Aguilar-Company
- Publisher
- SAGE Publications
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)